keyword
https://read.qxmd.com/read/38634023/mines-of-cytokine-a-treasure-trove-in-pulpal-and-periapical-diseases
#1
REVIEW
Neelam D Chandwani, Unnati Devanand Gedam, Ranjana Deshmukh, Darshan M Dakshindas, Manish Shrigiriwar
Pulpitis is a special disease of dental pulp. It causes localized inflammation, due to various inflammatory mediators such as cytokines and chemokines. These inflammatory mediators are responsible for various reparative and resorptive processes in the dental pulp. The balance between these processes ultimately determines the viability of the tooth. Due to the important properties of various inflammatory markers, the correlation of cytokinin gene expression in various stages of inflammation becomes necessary to focus on...
March 2024: J Conserv Dent Endod
https://read.qxmd.com/read/38631493/efficacy-and-safety-of-topical-0-5-5-fluorouracil-as-primary-treatment-of-ocular-surface-squamous-neoplasia
#2
REVIEW
Juliana Mika Kato, Priscilla Luppi Ballalai, Patricia Picciarelli de Lima, Ruth Miyuki Santo
OBJECTIVE: To assess the efficacy and safety of topical 0.5% 5-Fluorouracil (5-FU) as a primary therapy of ocular surface squamous neoplasia (OSSN). DESIGN: Retrospective study. PARTICIPANTS: Patients with clinically suspected OSSN referred to a Brazilian tertiary health center between October 2015 and December 2022. METHODS: After diagnostic confirmation of OSSN with exfoliative cytology, 0.5% 5-FU was administered topically 4 times daily for 2 weeks followed by a pause of 2 weeks...
April 14, 2024: Canadian Journal of Ophthalmology. Journal Canadien D'ophtalmologie
https://read.qxmd.com/read/38628035/tyk2-inhibition-with-deucravacitinib-ameliorates-erosive-oral-lichen-planus
#3
JOURNAL ARTICLE
Kim Natalie Stolte, Alberto Mesas-Fernández, Katharina Meier, Edis Kaan Klein, Henrik Dommisch, Kamran Ghoreschi, Farzan Solimani
Erosive oral lichen planus (OLP) is a challenging disease. This T cell driven disorder frequently shows a treatment unresponsive course and strongly limits patients' quality of life. The disease lacks FDA or EMA approved drugs for its treatment and the efficacy of the commonly administered treatments (i.e. topical and systemic steroids, steroid sparing agents) is often only partial. Although the etiopathogenesis of the disease still needs to be fully elucidated, recent advances helped to identify interferon-ɣ (IFN-ɣ) as a pivotal cytokine in OLP pathogenesis, thus making the interference with its signalling a therapeutic target...
April 2024: Experimental Dermatology
https://read.qxmd.com/read/38618926/evaluating-treatment-efficacy-in-hospitalized-covid-19-patients-with-applications-to-adaptive-covid-19-treatment-trials
#4
JOURNAL ARTICLE
Dan-Yu Lin, Jianqiao Wang, Yu Gu, Donglin Zeng
BACKGROUND: The current endpoints for therapeutic trials of hospitalized COVID-19 patients capture only part of the clinical course of a patient and have limited statistical power and robustness. METHODS: We specify proportional odds models for repeated measures of clinical status, with a common odds ratio of lower severity over time. We also specify the proportional hazards model for time to each level of improvement or deterioration of clinical status, with a common hazard ratio for overall treatment benefit...
April 15, 2024: Clinical Trials: Journal of the Society for Clinical Trials
https://read.qxmd.com/read/38615379/roles-of-irf4-in-various-immune-cells-in-systemic-lupus-erythematosus
#5
REVIEW
Ze Xiu Xiao, Rongzhen Liang, Nancy Olsen, Song Guo Zheng
Interferon regulatory factor 4 (IRF4) is a member of IRF family of transcription factors which mainly regulates the transcription of IFN. IRF4 is restrictively expressed in immune cells such as T and B cells, macrophages, as well as DC. It is essential for the development and function of these cells. Since these cells take part in the homeostasis of the immune system and dysfunction of them contributes to the initiation and progress of systemic lupus erythematosus (SLE), the roles of IRF4 in the SLE development becomes an important topic...
April 13, 2024: International Immunopharmacology
https://read.qxmd.com/read/38610078/janus-kinase-inhibitors-and-the-changing-landscape-of-vitiligo-management-a-scoping-review
#6
REVIEW
Amelia Utama, Ruki Wijesinghe, Steven Thng
Vitiligo is a chronic skin condition caused by an autoimmune response that results in the progressive loss of melanocytes and recent studies have suggested that Janus kinase inhibitors (JAKi) are emerging as a promising new treatment modality. Therefore, to assess and understand the extent of knowledge in the emerging field of JAKi use in vitiligo, a scoping review of the literature was undertaken. The reviewed articles explored a wide variety of JAKi administered either orally or topically for vitiligo. There were no injectable JAKi studied...
April 12, 2024: International Journal of Dermatology
https://read.qxmd.com/read/38605883/the-aconitate-decarboxylase-1-itaconate-pathway-modulates-immune-dysregulation-and-associates-with-cardiovascular-disease-markers-in-sle
#7
Eduardo Patiño-Martinez, Shuichiro Nakabo, Kan Jiang, Carmelo Carmona-Rivera, Wanxia Li Tsai, Dillon Claybaugh, Zu-Xi Yu, Aracely Romero, Eric Bohrnsen, Benjamin Schwarz, Miguel A Solís-Barbosa, Luz P Blanco, Mohammad Naqi, Yenealem Temesgen-Oyelakim, Michael Davis, Zerai Manna, Nehal Mehta, Faiza Naz, Stephen Brooks, Stefania dell'Orso, Sarfaraz Hasni, Mariana J Kaplan
OBJECTIVE: The Krebs cycle enzyme Aconitate Decarboxylase 1 (ACOD1) mediates itaconate synthesis in myeloid cells.. Previously, we reported that administration of 4-octyl itaconate abrogated lupus phenotype in mice. Here, we explore the role of the endogenous ACOD1/itaconate pathway in the development of murine lupus as well as their relevance in premature cardiovascular damage in SLE. METHODS: We characterized Acod1 protein expression in bone marrow-derived macrophages and human monocyte-derived macrophages, following a TLR7 agonist (imiquimod, IMQ)...
February 22, 2024: medRxiv
https://read.qxmd.com/read/38601193/unilateral-conjunctival-classic-kaposi-sarcoma-following-a-covid-19-booster
#8
Emily White, Nicholas Fazio, Konstantinos Tourmouzis, Samuel Ryu, Paul T Finger, Jodi Sassoon, Roger Keresztes, Timothy Chou, Kevin Kaplowitz, Robert Honkanen
PURPOSE: We describe a case of Classic Kaposi's sarcoma in a functionally monocular patient following a COVID19 vaccine booster and provide compelling evidence that suggests the booster was a relevant co-factor in the initiation of the disease process. OBSERVATIONS: The patient presented with red, irritated conjunctival area described as "bubbling" in her right eye. While her past medical history includes hypercholesterolemia and hypertension, she had no history of a compromised immune system...
June 2024: American Journal of Ophthalmology Case Reports
https://read.qxmd.com/read/38597902/efficacy-of-anifrolumab-in-long-term-intractable-alopecia-due-to-discoid-lupus-erythematosus
#9
JOURNAL ARTICLE
Naoto Azuma, Masaru Natsuaki, Naoaki Hashimoto, Takeo Abe, Suzu Ueda, Yuko Ohno, Masatoshi Jinnin, Kiyoshi Matsui
Alopecia associated with lupus erythematosus is broadly classified into reversible nonscarring alopecia seen in the acute phase, such as worsening of systemic lupus erythematosus (SLE) and cicatricial alopecia seen in chronic cutaneous lupus erythematosus represented by discoid lupus erythematosus (DLE). In DLE-induced alopecia, early therapeutic intervention before developing scarring alopecia is important, but the condition is often resistant to conventional treatment. Anifrolumab (ANI), a novel therapeutic agent for SLE that inhibits type I interferon activity, has been shown to be effective against acute skin lesions, including alopecia, in patients with SLE...
April 10, 2024: Modern rheumatology case reports
https://read.qxmd.com/read/38579666/formononetin-attenuates-psoriasiform-inflammation-by-regulating-interferon-signaling-pathway
#10
JOURNAL ARTICLE
Hao-Tian Xu, Qi Zheng, Zong-Guang Tai, Wen-Cheng Jiang, Shao-Qiong Xie, Yue Luo, Xiao-Ya Fei, Ying Luo, Xin Ma, Le Kuai, Ying Zhang, Rui-Ping Wang, Bin Li, Quan-Gang Zhu, Jian-Kun Song
BACKGROUND: Psoriasis is a long-lasting, inflammatory, continuous illness caused through T cells and characterized mainly by abnormal growth and division of keratinocytes. Currently, corticosteroids are the preferred option. However, prolonged use of traditional topical medication can lead to adverse reactions and relapse, presenting a significant therapeutic obstacle. Improved alternative treatment options are urgently required. Formononetin (FMN) is a representative component of isoflavones in Huangqi (HQ) [Astragalus membranaceus (Fisch...
February 4, 2024: Phytomedicine
https://read.qxmd.com/read/38563809/interferon-alpha-induces-psoriatic-inflammation-in-mice-by-phosphorylating-foxo3
#11
JOURNAL ARTICLE
Hanjiang Gu, Xiaoyu Wang, Mei Lu, Yaqi Wang, Kaixuan Ren, Yitian Zhang, Wei Liu, Guanglei Hu, Weihui Zeng, Yumin Xia
Psoriasis is a chronic, immune-mediated inflammatory skin disease characterized by epidermal thickening and inflammatory cell infiltration. Excessive proliferation of keratinocytes and resistance to apoptosis lead to thickening of the epidermis. Plasmacytoid dendritic cells are involved in the occurrence of psoriasis mainly by secreting interferon-alpha (IFN-α). IFN-α is a glycoprotein with antiviral, antitumor, and immunomodulatory effects, but its role in psoriasis remains unclear. In this investigation, a mild psoriatic phenotype was observed in mice upon topical application of IFN-α cream, and the inflammation was exacerbated when combined with imiquimod (IMQ)...
April 2, 2024: Journal of Interferon & Cytokine Research
https://read.qxmd.com/read/38531802/formononetin-restrains-tumorigenesis-of-breast-tumor-by-restraining-sting-nf-%C3%AE%C2%BAb-and-interfering-with-the-activation-of-pd-l1
#12
JOURNAL ARTICLE
Hongmei Liu, Zhipeng Wang, Zhigang Liu
BACKGROUND: Breast cancer (BC), a common tumor in women, has high morbidity and mortality. Formononetin, an active ingredient in red clover and Astragalus membranaceus , has a wide range of pharmacological applications, including as an anticancer agent. Since immunotherapy is a hot topic in the treatment strategy of BC, it was dedicated to appraising the specific mechanism of formononetin in BC immunotherapy in this research. METHODS: Different formononetin concentrations (0, 20, 40, 60, 80, 100 μM) were used to treat BC cells transfected with pcDNA3...
March 2024: Discovery Medicine
https://read.qxmd.com/read/38521390/topical-5-fluorouracil-1-for-moderate-to-extensive-ocular-surface-squamous-neoplasia-in-73-consecutive-patients-primary-versus-secondary-treatment
#13
JOURNAL ARTICLE
Irwin Leventer, Hartej Singh, Bahram Pashaee, Christian D Raimondo, Chenab K Khakh, Jonathan L Martin, Binod Acharya, Qiang Zhang, Sara E Lally, Carol L Shields
IMPORTANCE: Ocular surface squamous neoplasia (OSSN) is a spectrum of malignancies that generally includes conjunctival intraepithelial neoplasia (CIN) and squamous cell carcinoma (SCC). OSSN can be treated with topical therapies including interferon α-2b (IFN), mitomycin C (MMC), or 5-fluorouracil 1% (5FU). Recently, due to unavailability of IFN and toxicity associated with MMC, therapy has shifted towards 5FU. OBJECTIVE: Herein, we compare the use of 5FU 1% as a primary versus (vs) secondary treatment regimen in eyes with moderate to extensive OSSN...
March 21, 2024: Asia-Pacific Journal of Ophthalmology
https://read.qxmd.com/read/38513130/chronic-radiation-dermatitis-secondary-to-narrow-band-ultraviolet-b-therapy-in-a-patient-with-primary-cutaneous-cd8-t-cell-lymphoma-with-cytotoxic-granules
#14
JOURNAL ARTICLE
Mia P Edelson, Jane J Gay, Robert W Thiel, Douglas J Grider
Conventional therapies for CD8+ cutaneous T-cell lymphoma include topical steroids, topical nitrogen mustard, topical bexarotene, ultraviolet B therapy, psoralen and ultraviolet A therapy, local radiotherapy, and interferon alfa; however, these treatments are often found to be ineffective. Presented is a case of CD8+ cutaneous T-cell lymphoma with near-complete response to narrow-band ultraviolet therapy because of chronic radiation dermatitis initially believed to be possible progression of a CD8+ cutaneous epidermotropic cytotoxic T-cell lymphoma...
March 12, 2024: American Journal of Dermatopathology
https://read.qxmd.com/read/38491743/an-update-on-clinical-trials-for-cutaneous-lupus-erythematosus
#15
REVIEW
Lillian Xie, Lais Lopes Almeida Gomes, Caroline J Stone, Daniella Forman Faden, Victoria P Werth
Cutaneous lupus erythematosus (CLE) comprises dermatologic manifestations that may occur independently or with systemic lupus erythematosus (SLE). Despite advancements in refining CLE classification, establishing precise subtype criteria remains challenging due to overlapping presentations and difficulty in distinguishing morphology. Current treatments encompass preventive measures, topical therapies, and systemic approaches. Hydroxychloroquine and glucocorticoids are the sole US Food and Drug Administration (FDA)-approved medications for CLE, with numerous off-label treatments available...
March 15, 2024: Journal of Dermatology
https://read.qxmd.com/read/38454855/reserve-drug-as-first-line-management-topical-interferon-%C3%AE-2b-for-vernal-keratoconjunctivitis
#16
JOURNAL ARTICLE
Saurabh Ramdas Haral, Taskin Khan, Vishnu S Gupta, Madhura Sanjay Ukalkar
PURPOSE: To elucidate the efficacy and safety profile of interferon α-2b in vernal keratoconjunctivitis (VKC). METHODS: In this prospective interventional study, VKC patients fulfilling the inclusion and exclusion criteria were included and their signs and symptoms were scored based on the Clinical Scoring System. Patients were treated with topical interferon α-2b eye drop (1 MIU/ml) QID dosing for 6 weeks. Changes in symptoms and signs were evaluated at 2, 4, 8 weeks and 6 months after initiating treatment...
March 8, 2024: Indian Journal of Ophthalmology
https://read.qxmd.com/read/38441022/liposomes-an-emerging-strategy-for-the-effective-treatment-of-rheumatoid-arthritis
#17
JOURNAL ARTICLE
Vani, Priyanka Kriplani, Ashwani Dhingra, Bhawna Chopra, Ajmer Singh Grewal, Geeta Deswal, Rameshwar Dass, Kumar Guarve
BACKGROUND: A Liposomal delivery system is a novel and distinguishing way of organized medicine administration. The advancements in liposomal technology allow for controlled drug distribution to treat rheumatoid arthritis effectively. Liposomes are microscopic lipid-based vesicles that have shown promise in transporting substances, such as superoxide dismutase, hemoglobin, erythrocyte interleukin-2, gamma interferon, and smaller compounds. OBJECTIVE: Liposomes are biocompatible, nontoxic, biodegradable, non-immunogenic, and flexible, with sizes ranging from 0...
March 4, 2024: Current Rheumatology Reviews
https://read.qxmd.com/read/38440158/enhancing-efficacy-and-quality-of-life-in-patients-with-herpes-zoster-infection-in-hairy-cell-leukemia
#18
Xiaowei Feng, Yuchen Tao, Qi Hu, Yuanxia Liu, Jizhang Bao, Wenwen Jiang
Hairy cell leukemia (HCL) is an infrequent and persistent B-cell inert lymphoid leukemia. In this study, we present the case of a 71-year-old female patient with a previous diagnosis of variant HCL who experienced a severe herpes zoster infection leading to an extensive skin eruption. The patient's initial diagnosis of HCL occurred 7 years ago, and she underwent treatment with cladribine, interferon, COP (cyclophosphamide, vincristine, and prednisone), benztropine tablets + clarithromycin dispersible, and ibrutinib...
2024: Case Reports in Hematology
https://read.qxmd.com/read/38432019/topical-delivery-of-drugs-in-the-treatment-of-high-grade-cervical-squamous-intraepithelial-lesions-a-meta-analysis
#19
JOURNAL ARTICLE
Shixuan Liu, Wenlei Zhang, Wenyan Wang, Jianlan Zheng
OBJECTIVE: The present study aims to evaluate the efficacy and effect of localized delivery of drugs in the treatment of high-grade squamous intraepithelial lesion (HSIL) based on a meta-analysis. STUDY DESIGN: Databases including Cochrane Library, PubMed, Embase, Scopus, CNKI, and Wanfang were searched from their inception till August 2022. Randomized controlled trials (RCTs) that compared the efficacy of drugs and surgery in the treatment of HSIL were collected...
February 20, 2024: European Journal of Obstetrics, Gynecology, and Reproductive Biology
https://read.qxmd.com/read/38425639/xeroderma-pigmentosum-with-ocular-surface-squamous-neoplasia-a-case-report
#20
Sravanthi Malikireddy
Xeroderma pigmentosum (XP) is a rare, autosomal recessive disorder characterized by defective DNA repair. Patients with this disorder are at increased risk of developing various oculocutaneous malignancies. We report a rare case of a child with XP with bilateral ocular surface squamous neoplasia (OSSN) and left eye (OS) medial canthal basal cell carcinoma (BCC)...
January 2024: Curēus
keyword
keyword
166663
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.